Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension
Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension
Publisher:
New England Journal of Medicine
Date published:
2013
Record type:
Journal Title:
The New England Journal of Medicine
Source:
The New England Journal of Medicine, Vol. 369, No. 9, August 29, 2013, pp. 809-818
Abstract:
In an event-driven trial, macitentan (an endothelin-receptor antagonist) at a dose of 3 or 10 mg was compared with placebo in patients with symptomatic pulmonary arterial hypertension. At a median of 115 weeks, both macitentan doses were associated with reduced morbidity and mortality.
Language:
Catagory URL:
CITATION: Pulido, T. [etal]. Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension . : New England Journal of Medicine , 2013. The New England Journal of Medicine, Vol. 369, No. 9, August 29, 2013, pp. 809-818 - Available at: https://library.au.int/macitentan-and-morbidity-and-mortality-pulmonary-arterial-hypertension-4